ライフサイエンスコーパス: ibritumomab tiuxetan

1 at of control groups who did not receive 90Y ibritumomab tiuxetan.

2 apy given to patients who relapsed after 90Y ibritumomab tiuxetan.

3 tients (50 eligible patients) received (90)Y-ibritumomab tiuxetan.

4 on was the primary toxicity noted with (90)Y ibritumomab tiuxetan.

5 lar to that in patients not treated with 90Y ibritumomab tiuxetan.

6 ovel conditioning regimen combining NMA with ibritumomab tiuxetan.

7 ntravenously administered (111)In- and (90)Y-ibritumomab tiuxetan.

8 Abs) (131)iodine-tositumomab and (90)yttrium-ibritumomab tiuxetan.

9 weight-based dosing regimen used with (90)Y-ibritumomab tiuxetan.

10 /- 1.64 GBq (range, 0.42-7.54 GBq) for (90)Y-ibritumomab tiuxetan.

11 (2-24 h) after the administration of (111)In-ibritumomab tiuxetan.

12 t 2-24 h after the administration of (111)In-ibritumomab tiuxetan.

13 the beta-emitting radiopharmaceutical (90)Y-ibritumomab tiuxetan.

14 e studies of outpatient treatment with (90)Y ibritumomab tiuxetan.

15 patients using (131)I-tositumomab and (90)Y-ibritumomab tiuxetan.

16 ion on five separate protocols that used 90Y ibritumomab tiuxetan 0.4 mCi/kg.

17 later with rituximab (250 mg/m(2)) and (90)Y ibritumomab tiuxetan (0.3 mCi/kg [11 MBq/kg]).

18 ioimmunotherapy with a reduced dose of (90)Y ibritumomab tiuxetan (0.3 mCi/kg [11 MBq/kg]; maximum 32

19 ubsequently performed a trial in which (90)Y-ibritumomab tiuxetan (0.4 mCi/kg) was added to the fluda

20 te peripheral blood B cells, then yttrium-90 ibritumomab tiuxetan (0.4 mCi/kg; maximum, 32 mCi) intra

21 odgkin's lymphoma received standard-dose 90Y ibritumomab tiuxetan (14.8 MBq/kg [0.4 mCi/kg]) followed

22 adioimmunotherapy for NHL (20 received (90)Y-ibritumomab tiuxetan; 18 received (131)I-tositumomab).

23 to treat was made after imaging with (111)In-ibritumomab tiuxetan (4.0% of all cases captured); 16 of

24 ximab (250 mg/m(2)) and injection of (111)In ibritumomab tiuxetan (5 mCi [185 MBq]) for dosimetry eva

25 An imaging/dosimetry dose of indium-111 ibritumomab tiuxetan (5 mCi) was injected after rituxima

26 Of the responders, 29.5% used only (90)Y-ibritumomab tiuxetan, 7.6% used only (131)I-tositumomab,

27 efficacy and toxicity of fractionated (90)Y-ibritumomab tiuxetan ((90)Y-IT) as initial therapy of fo

28 a multicenter phase II trial of (90)yttrium-ibritumomab-tiuxetan ((90)YIT) as first-line stand-alone

29 ted that when measuring all volumes of (90)Y-ibritumomab tiuxetan activity prescriptions, only a sing

30 = 150,000 cells/mm(3) for the standard (90)Y-ibritumomab tiuxetan administered dose (15 MBq/kg [0.4 m

31 = 100,000 cells/mm(3) for the reduced (90)Y-ibritumomab tiuxetan administered dose (7.4-11 MBq/kg [0

32 Both ibritumomab tiuxetan administered doses were preceded by

33 on absorbed doses for (111)In- and for (90)Y-ibritumomab tiuxetan administered to 10 cancer patients

34 atients and their family members after (90)Y-ibritumomab tiuxetan administration.

35 pproximately 400) was not treated with (90)Y-ibritumomab tiuxetan after imaging with (111)In-ibritumo

36 single-center clinical experience with (90)Y-ibritumomab tiuxetan and (131)I-tositumomab for therapy

37 d not significantly differ between the (90)Y-ibritumomab tiuxetan and (131)I-tositumomab groups.

38 (mean +/- SD, 3.418 +/- 1.49) and that (90)Y-ibritumomab tiuxetan and (131)I-tositumomab were expensi

39 Both (90)Y-ibritumomab tiuxetan and (131)I-tositumomab were well to

40 n 57% and 56% of patients treated with (90)Y-ibritumomab tiuxetan and (131)I-tositumomab, respectivel

41 reports of the efficacy and safety of (90)Y-ibritumomab tiuxetan and (131)I-tositumomab, these thera

42 both 14-27 days before treatment with (90)Y-ibritumomab tiuxetan and 4-6 months after treatment.

43 enters, were administered the tracer (111)In-ibritumomab tiuxetan and assessed using planar scintilla

44 dministration approval for marketing - Y(90) ibritumomab tiuxetan and I(131) tositumomab, given as th

45 The single-agent activity of (90)Y-ibritumomab tiuxetan and its favorable safety profile wa

46 e declines in platelet counts than did (90)Y-ibritumomab tiuxetan and may be a more appropriate choic

47 nse (CR) rates were 30% and 16% in the (90)Y ibritumomab tiuxetan and rituximab groups, respectively

48 ared with previously published dosimetry for ibritumomab tiuxetan and the product package insert.

49 (90)Y- and (131)I-anti-CD20 antibodies (ibritumomab tiuxetan and tositumomab, respectively) have

50 d more frequently after treatment with (90)Y-ibritumomab tiuxetan and was associated with prolongatio

51 With the approval of (90)Y-ibritumomab tiuxetan, and based on the results of numero

52 d and Drug Administration has approved (90)Y-ibritumomab tiuxetan anti-B-cell NHL mAb as the first co

53 (111)In- and (90)Y-ibritumomab tiuxetan are labeled at commercial radiophar

54 We hypothesized that (9)(0)Y-ibritumomab tiuxetan-based NMAT would facilitate early c

55 itumomab tiuxetan after imaging with (111)In-ibritumomab tiuxetan, because of altered biodistribution

56 tic regimen in patients treated with (111)In-ibritumomab tiuxetan between March 27, 2002, and March 3

57 imab to clear peripheral B-cells and improve ibritumomab tiuxetan biodistribution.

58 We conclude that high-dose 90Y-ibritumomab tiuxetan can be combined safely with high-do

59 CHOP given for four cycles followed by (90)Y-ibritumomab tiuxetan compared favorably with historical

60 (90)Y-ibritumomab tiuxetan consists of a murine monoclonal ant

61 with 3 cycles of CHOP plus IFRT followed by ibritumomab tiuxetan consolidation had outcomes that com

62 313 trial, we evaluated the impact of adding ibritumomab tiuxetan consolidation to 3 cycles of standa

63 The median 90Y-ibritumomab tiuxetan dose was 71.6 mCi (2649.2 MBq; rang

64 ived 0.4 mCi/kg (maximum, 32 mCi/kg) (9)(0)Y-ibritumomab tiuxetan, fludarabine, and 2 Gy total body i

65 simetry (day -21) with 5 mCi (185 MBq) 111In-ibritumomab tiuxetan following 250 mg/m2 rituximab, foll

66 e biodistribution and one dose of indium-111 ibritumomab tiuxetan for imaging and dosimetry.

67 rituximab, 250 mg/m(2), followed by (111)In-ibritumomab tiuxetan, for imaging, on day 1 and a dose o

68 1 and a dose of rituximab followed by (90)Y-ibritumomab tiuxetan, for therapy, on day 7, 8, or 9.

69 he safety and efficacy of yttrium-90 ((90)Y) ibritumomab tiuxetan given as consolidation of complete

70 rophil count nadir was shorter for the (90)Y-ibritumomab tiuxetan group than for the (131)I-tositumom

71 radioimmunotherapy was greater in the (90)Y-ibritumomab tiuxetan group than in the (131)I-tositumoma

72 ion of response was 14.2 months in the (90)Y ibritumomab tiuxetan group versus 12.1 months in the con

73 ORR was 80% for the (90)Y ibritumomab tiuxetan group versus 56% for the rituximab

74 The predominant toxicity of 90Y ibritumomab tiuxetan has been myelosuppression, and conc

75 Yttrium-90 ibritumomab tiuxetan (IDEC-Y2B8) is a murine immunoglobu

76 t-Line Indolent Trial of yttrium-90 ((90)Y) -ibritumomab tiuxetan in advanced-stage follicular lympho

77 conducted a phase 1/2 trial of high-dose 90Y-ibritumomab tiuxetan in combination with high-dose etopo

78 r (131)I-tositumomab and the liver for (90)Y-ibritumomab tiuxetan in myeloablative NHL treatment regi

79 he safety and efficacy of yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients with relapsed or refrac

80 This study evaluated ibritumomab tiuxetan in the treatment of rituximab-refra

81 In summary, (90)Y-ibritumomab tiuxetan introduces (90)Y into clinical prac

82 90Y-ibritumomab tiuxetan is a novel radioimmunotherapeutic a

83 Ibritumomab tiuxetan is an anti-CD20 murine IgG1 kappa m

84 (90)Y-ibritumomab tiuxetan is dosed on the basis of the patien

85 transplantation after prior therapy with 90Y ibritumomab tiuxetan is feasible and reasonably well tol

86 emissions associated with the therapy, (90)Y-ibritumomab tiuxetan is routinely administered on an out

87 Reduced-dose ibritumomab tiuxetan is safe and well tolerated and has

88 Radioimmunotherapy with (90)Y ibritumomab tiuxetan is well tolerated and produces stat

89 Dose-escalated (90)Y ibritumomab tiuxetan may be safely combined with high-do

90 ents received 131I-tositumomab (n=23) or 90Y-ibritumomab tiuxetan (n=10) and underwent 18F-FDG PET/CT

91 ioimmunotherapy with 131I-tositumomab or 90Y-ibritumomab tiuxetan not only induces high response rate

92 administered dose of 185 MBq (5 mCi) (111)In-ibritumomab tiuxetan on day 0, evaluated with dosimetry,

93 dose of 7.4-15 MBq/kg (0.2-0.4 mCi/kg) (90)Y-ibritumomab tiuxetan on day 7.

94 roved anti-CD20 radioimmunoconjugates ((90)Y-ibritumomab tiuxetan or (131)I-tositumomab) have had enc

95 Ibritumomab tiuxetan produces durable responses in patie

96 Ibritumomab tiuxetan radioimmunotherapy is effective in

97 Ibritumomab tiuxetan radioimmunotherapy targets the same

98 genous leukemia (t-AML) after treatment with ibritumomab tiuxetan radioimmunotherapy.

99 Yttrium Y 90 ibritumomab tiuxetan, recently approved by the Food and

100 on-Hodgkin's lymphoma (NHL) treated with the ibritumomab tiuxetan regimen in registration and compass

101 The ibritumomab tiuxetan regimen included an infusion of rit

102 An ibritumomab tiuxetan regimen was initiated 3 to 6 weeks

103 ear to be increased after treatment with the ibritumomab tiuxetan regimen.

104 alone, at which one may underestimate (90)Y-ibritumomab tiuxetan response by considering inactive re

105 kinetic data from 4 clinical trials of (90)Y-ibritumomab tiuxetan RIT for relapsed or refractory B-ce

106 Single-dose (90)Y ibritumomab tiuxetan RIT has an acceptable safety profil

107 ment by NHL can be treated safely with (90)Y-ibritumomab tiuxetan RIT on the basis of a fixed, weight

108 use of a procedure for radiolabeling (111)In-ibritumomab tiuxetan that differed from that in the pres

109 The ibritumomab tiuxetan therapeutic regimen consists of a d

110 s to verify completion of treatment with the ibritumomab tiuxetan therapeutic regimen in patients tre

111 of an estimated 1,144-1,192 patients in whom ibritumomab tiuxetan therapy was initiated (case capture

112 antation with stem cells collected after 90Y ibritumomab tiuxetan therapy.

113 compared to patients who did not receive 90Y ibritumomab tiuxetan, there was no significant differenc

114 g/m2 rituximab, followed a week later by 90Y-ibritumomab tiuxetan to deliver a target dose of 1000 cG

115 Adding 90Y ibritumomab tiuxetan to high-dose BEAM with autologous s

116 The addition of (9)(0)Y-ibritumomab tiuxetan to NMAT is safe and yields early re

117 ad experienced disease progression after 90Y ibritumomab tiuxetan treatment and received subsequent t

118 The ibritumomab tiuxetan treatment regimen consisted of pret

119 ble superior assessment of response to (90)Y-ibritumomab tiuxetan treatment than the use of CT alone,

120 131I-tositumomab and those who received 90Y-ibritumomab tiuxetan was demonstrated (-31%+/-51% vs. -4

121 The therapeutic dose of (90)Y ibritumomab tiuxetan was followed by high-dose BEAM and

122 ies, (131)iodine-tositumomab and (90)yttrium-ibritumomab tiuxetan, were FDA-approved more than a deca

123 icroL received a dose of 0.4 mCi/kg of (90)Y-ibritumomab tiuxetan, whereas those with a platelet coun

124 novel radioimmunotherapy yttrium-90 ((90)Y) ibritumomab tiuxetan with a control immunotherapy, ritux

125 y and efficacy of combining yttrium-90 (90Y) ibritumomab tiuxetan with high-dose carmustine, cytarabi

126 d at 2-24 h and at 48-72 h after the (111)In-ibritumomab tiuxetan, with an optional third scan at 90-

127 Two radioimmunoconjugates, ibritumomab tiuxetan (Zevalin) and tositumomab-131I (Bex

128 eviously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT)

129 Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin; IDEC Pharmaceutical, San

130 ssion (CR) before transplant by adding (90)Y-ibritumomab-tiuxetan (Zevalin) to the high-dose regimen.

131 90 ((90)Y)-labeled anti-CD20 antibody ((90)Y ibritumomab tiuxetan; Zevalin, IDEC Pharmaceuticals Corp